Investigation of the pathogenesis and development of new treatments for autoimmune diseases, such as systemic lupus erythematosus

Investigation of the pathogenesis and development of new treatments for autoimmune diseases, such as systemic lupus erythematosus - Pathogenesis and new treatments for autoimmune diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007012

Enrollment

Registered

2012-02-01

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

Drawing peripheral blood

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: People who had informed consent to this study

Exclusion criteria

Exclusion criteria: People who did not have informed consent to this study

Design outcomes

Primary

Measure	Time frame
TCR zeta expression on PBMC and Serum inflammatory cytokines before immunosuppressive therapy	—

Secondary

Measure	Time frame
Change of the above findings after immunosuppressive treatment	—

Countries

Japan

Contacts

Public ContactKoichi Amano

Saitama Medical Center, Saitama Medical Universitity Department of Rheumatology & Clinical Immunology

amanokoi@saitama-med.ac.jp049-228-3859

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026